Cite
Schrezenmeier H, Kulasekararaj A, Mitchell L, et al. One-year efficacy and safety of ravulizumab in adults with paroxysmal nocturnal hemoglobinuria naïve to complement inhibitor therapy: open-label extension of a randomized study. Ther Adv Hematol. 2020;11:2040620720966137doi: 10.1177/2040620720966137.
Schrezenmeier, H., Kulasekararaj, A., Mitchell, L., Sicre de Fontbrune, F., Devos, T., Okamoto, S., Wells, R., Rottinghaus, S. T., Liu, P., Ortiz, S., Lee, J. W., & Socié, G. (2020). One-year efficacy and safety of ravulizumab in adults with paroxysmal nocturnal hemoglobinuria naïve to complement inhibitor therapy: open-label extension of a randomized study. Therapeutic advances in hematology, 112040620720966137. https://doi.org/10.1177/2040620720966137
Schrezenmeier, Hubert, et al. "One-year efficacy and safety of ravulizumab in adults with paroxysmal nocturnal hemoglobinuria naïve to complement inhibitor therapy: open-label extension of a randomized study." Therapeutic advances in hematology vol. 11 (2020): 2040620720966137. doi: https://doi.org/10.1177/2040620720966137
Schrezenmeier H, Kulasekararaj A, Mitchell L, Sicre de Fontbrune F, Devos T, Okamoto S, Wells R, Rottinghaus ST, Liu P, Ortiz S, Lee JW, Socié G. One-year efficacy and safety of ravulizumab in adults with paroxysmal nocturnal hemoglobinuria naïve to complement inhibitor therapy: open-label extension of a randomized study. Ther Adv Hematol. 2020 Oct 24;11:2040620720966137. doi: 10.1177/2040620720966137. eCollection 2020. PMID: 33178408; PMCID: PMC7592174.
Copy
Download .nbib